ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) (TOFA-SSc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03274076
Recruitment Status : Active, not recruiting
First Posted : September 6, 2017
Last Update Posted : September 5, 2018
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Dinesh Khanna, MD, MS, University of Michigan

Brief Summary:
This study will evaluate tofacitinib treatment in subjects with diffuse cutaneous systemic scleroderma (dcSSc) in a placebo controlled trial. This phase I/II study is intended to provide safety, and tolerability data in participants with dcSSc when dosed to target exposures similar to that used in adult participants with RA.

Condition or disease Intervention/treatment Phase
Systemic Sclerosis Scleroderma Drug: Tofacitinib Drug: Placebo Oral Tablet Phase 1 Phase 2

Detailed Description:
The purpose of this clinical research study is to evaluate the safety, tolerability and efficacy of treatment with tofacitinib (study drug) versus placebo (a substance with no active ingredients and therefore may have no treatment benefit) in people with diffuse cutaneous systemic scleroderma. Subjects will be randomized to tofacitinib vs. placebo in a 2:1 ratio at 5 mg twice a day for 24 weeks. Subjects will then be offered to participate in an open label phase during which they will receive tofacitinib 5 mg twice a day for 24 weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Eligible subjects will be randomized to tofacitinib or placebo in a 2:1 manner.
Masking: Double (Participant, Investigator)
Masking Description: The study staff (with the exception of the study pharmacist) and the patient are blinded to the treatment assignment.
Primary Purpose: Treatment
Official Title: Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study
Actual Study Start Date : October 2, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : April 2020


Arm Intervention/treatment
Active Comparator: Tofacitinib
5mg Tofacitinib twice a day
Drug: Tofacitinib
Oral medication tofacitinib 5 mg twice a day for 24 weeks.
Other Name: Xeljanz

Placebo Comparator: Placebo
5mg Placebo twice a day
Drug: Placebo Oral Tablet
Oral Placebo 5 mg twice a day for 24 weeks




Primary Outcome Measures :
  1. Incidence of adverse events (AEs) and Serious AE (SAEs) [ Time Frame: 24 weeks ]
    The primary endpoint will be the proportion of participants who experience Grade 3 or higher adverse events that occur at or before Week 24.


Secondary Outcome Measures :
  1. Number of Grade 3(severe) or higher adverse events that occur throughout the study [ Time Frame: Week: 12, Week 36, Week 48 ]
    Grade 3 or higher adverse events (AEs) assessed throughout the study

  2. Number of Grade 2 (moderate) or higher adverse events that occur throughout the study [ Time Frame: Week: 12, 24, 36, and 48 ]
    Grade 2 or higher assessed 12 weeks apart.

  3. Adverse events of special interest [ Time Frame: Week: 12, 24, 36, and 48 ]
    AESI that occur throughout the study

  4. Change in modified Rodnan Skin Score (mRSS) [ Time Frame: Week: 12, 24, 36, and 48 ]
    Change in skin thickness during the course of the study.

  5. Provisional American College of Rheumatology Combined Response Index Systemic Sclerosis [ Time Frame: Week:12, 24, and 48 ]
    Number of events that meet CRISS ( Combined Response Index) criteria


Other Outcome Measures:
  1. Modified Rodnan Skin Score (MRSS) improvement [ Time Frame: Baseline, 12 and 24 weeks ]
    Proportion of subjects with mRSS improvement of 20%, 40%, and 60%

  2. Gastrointestinal symptoms assessed by UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) [ Time Frame: Baseline and weeks 12, 24, 26 and 48 ]
  3. Percent predicted Forced Vital Capacity (FVC) [ Time Frame: Baseline and weeks 12, 24 and 48 ]
  4. Change in left ventricular ejection [ Time Frame: Baseline and week 24 ]
  5. Change in tricuspid regurgitation [ Time Frame: Baseline and week 24 ]
  6. Physician's global assessment on a Likert scale [ Time Frame: Baseline and weeks 12, 24, 36, 48 ]
  7. Patients's global assessment on a Likert scale [ Time Frame: Baseline and weeks 12, 24, 36 and 48 ]
  8. Health-related quality of life (HRQOL) using Patient Reported Outcomes Measurement Information System (PROMIS) 29 2.0 [ Time Frame: Baseline and weeks 12, 24, 36 and 48 ]
  9. Physical function as assessed by the scleroderma health assessment questionnaire-disability index (SHAQ-DI) [ Time Frame: Baseline and weeks 12, 24, 36 and 48 ]
  10. Scleroderma-related skin symptoms assessed by Patient Reports Outcome for Scleroderma Related Skin Symptoms.(PRO-SRSS) [ Time Frame: Baseline and weeks 12, 24, 36 and 48 ]
  11. Comparison of average, most representative, and maximum skin score methodology for mRSS [ Time Frame: Every 6 weeks from baseline to week 48 with the exception of week 42 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of systemic sclerosis (SSc), as classified using the 2013 American College of Rheumatology/ European Union League Against Rheumatism classification of SSc.
  2. Diffuse Cutaneous Systemic Sclerosis (dcSSc) as defined by 2001 LeRoy and Medsger
  3. Disease duration ≤ 60 months (defined as time from the first non−Raynaud phenomenon manifestation)
  4. Modified Rodnan Skin Score (mRSS) units ≥ 10 and ≤ 45 at screening.
  5. Agreement to receive varicella-zoster vaccination (Zostavax®) or have received vaccination prior to screening.
  6. Oral corticosteroids (≤ 10 mg/day of prednisone or equivalent) are permitted if the patient is on a stable dose regimen for ≥ 2 weeks prior to and including the baseline visit.
  7. Ability to provide informed consent.

Exclusion Criteria:

  1. Rheumatic disease other than dcSSc; it is acceptable to include patients with fibromyalgia, Sjogren syndrome, and scleroderma-associated myopathy
  2. Limited cutaneous SSc or sine scleroderma
  3. Major surgery (including joint surgery) within 8 weeks prior to baseline.
  4. Any infected ulcer at screening
  5. Subjects with any serious bacterial infection within the last 3 months, unless treated and resolved with antibiotics, or any chronic bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, or bronchiectasis)
  6. Oral corticosteroids >10 mg/day of prednisone or equivalent.
  7. Hydroxychloroquine >400 mg/day, methotrexate >25 mg/week, D-Penicillamine >1000mg/day or mycophenolate mofetil > 2 grams/day prior to baseline. **Subjects can be on combination therapy of hydroxychloroquine and methotrexate or hydroxychloroquine and mycophenolate mofetil and must have been on a stable dose for at least 1month prior to baseline visit.
  8. Prior history of treatment in the 3 months prior to baseline with biological disease modifying anti-rheumatic drugs (DMARDs)potent immunosuppressants such as cyclosporine and azathioprine
  9. Treatment with etanercept within ≤ 2 weeks of baseline: infliximab, certolizumab, golimumab, abatacept, tocilizumab, or adalimumab within ≤ 8 weeks of baseline; and anakinra within ≤ 1 week prior to the baseline visit.
  10. Intravenous corticosteroids within 2 weeks prior to baseline visit.
  11. Treatment with any investigational agent ≤ 4 weeks prior to baseline (or 5 half-lives of the investigational drug, whichever is longer)
  12. Other investigational or marketed biologics with immunomodulatory properties within 3 months prior to baseline.
  13. Treatment with anti-CD20 6 months prior to baseline and B cell counts <LLN
  14. Any prior treatment with cell-depleting therapies other than anti-CD20 such as CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19
  15. Any prior treatment with chlorambucil, bone marrow transplantation, or total lymphoid irradiation
  16. Vaccinated or exposed to a live/attenuated vaccine (other than Zostavax®) ≤ 6 weeks prior to baseline; or is expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study medication. (**See additional inclusion for obtaining Zostavax® prior to entering the study)
  17. Pulmonary disease with FVC ≤ 50% of predicted, or DLCO (uncorrected for hemoglobin) ≤ 40% of predicted
  18. History of pulmonary arterial hypertension (PAH) with mean PAP> 30 mmHg on right heart catheterization requiring subcutaneous or intravenous prostacyclin or dual use of oral PAH therapies
  19. Subjects at risk for tuberculosis (TB):

    A. Specifically excluded from this study will be participants with a history of active TB within the last 3 years, even if it was treated; a history of active TB greater than 3 years ago, unless there is documentation that the prior anti-TB treatment was appropriate in duration and type; current clinical, radiographic, or laboratory evidence of active TB; (TB results within 30 days of screening will be accepted and will not to be repeated. B. Latent TB at or within 30 days of screening, history of or current positive purified protein derivative tuberculin skin test (PPD) ( >5mm induration, regardless of Bacille Calmette Guerin [BCG] vaccine and/or QuantiFERON Gold, a negative chest x-ray, and no symptoms or risk factors), unless one month of prophylaxis has been completed prior to inclusion

    • An indeterminate QuantiFERON® unless followed by a subsequent negative PPD or negative QuantiFERON® or a consultation with and clearance by local infectious disease (ID) department is required.
  20. Positive for hepatitis B surface antigen at or within 30 days of screening
  21. Positive for hepatitis C antigen at or within 30 days of screening
  22. Current or recent history of uncontrolled clinically significant renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
  23. History of HIV (as determined by medical records or patient reported).
  24. History of diverticulitis or chronic, ulcerative lower gastrointestinal (GI) disease such as Crohns disease, ulcerative colitis, or other symptomatic, lower GI conditions that might predispose a patient to perforations.
  25. Pregnant or breastfeeding female subjects; land female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in the protocol for the duration of the study and for at least 28 days after discontinuation of study drug.
  26. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation and in the judgment of the investigator would make the subject inappropriate for entry into this study.
  27. History of systemic sclerosis (SSc) Renal Crisis within the 6 months prior to baseline.
  28. Any of the following lab results at screening:

    • Hemoglobin <9 g/dL or Hematocrit <30%
    • White Blood Cell count <3.0 x 109/L;
    • Absolute Neutrophil count <1.2 x 109/L;
    • White Blood Cell count <3.0 x 109/L;
    • Absolute Neutrophil count <1.2 x 109/L;
    • Platelet count <100 x 109/L;
    • Absolute Lymphocyte count <0.75 x 109/L.
    • ALT or AST > 1.5 × the upper limit of normal (ULN) of normal at screening or any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the patient's participation in the study
    • Total bilirubin > ULN at Screening.
    • Estimated glomerular filtration rate [GFR] <40mL/min/1.73 m2
  29. Prior rituximab use without documentation of normalized b cell counts.
  30. History of recurrent (more than one episode) herpes zoster or disseminated (at least one episode) herpes zoster, or disseminated (at least one episode) herpes simplex
  31. History of any lymphoproliferative disorder, such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, leukemia, or signs and symptoms suggestive of current lymphatic disease.
  32. History of any malignancy in the last 5 years with the exception of adequately treated or excised basal cell or squamous cell or cervical cancer in situ.
  33. Significant trauma or surgery procedure within 1 month prior to first dose of study drug.
  34. History of alcohol or substance abuse, unless in full remission for greater than 6 months prior to first dose of study drug.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03274076


Locations
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48104
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
Sponsors and Collaborators
University of Michigan
Pfizer
Investigators
Principal Investigator: Dinesh Khanna, MD University of Michigan

Responsible Party: Dinesh Khanna, MD, MS, Frederick G L Huetwell Professor of Rheumatology and Professor of Internal Medicine, Medical School, University of Michigan
ClinicalTrials.gov Identifier: NCT03274076     History of Changes
Other Study ID Numbers: HUM000131837
First Posted: September 6, 2017    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Dinesh Khanna, MD, MS, University of Michigan:
diffuse
scleroderma
systemic sclerosis

Additional relevant MeSH terms:
Sclerosis
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Tofacitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action